公开(公告)号：EP2850067B1

公开(公告)日：2017-08-16

申请号：EP13791057.6

申请日：2013-05-17

申请人： Sumitomo Dainippon Pharma Co., Ltd.

发明人： HORI, Seiji ,  HASEGAWA, Futoshi ,  URABE, Daisuke ,  KUREBAYASHI, Hirotaka

IPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61P11/00 ,  A61P31/00 ,  A61P35/00 ,  A61P43/00 ,  C07D239/47 ,  C07D403/10 ,  C07D403/12

CPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  C07D239/47 ,  C07D239/49 ,  C07D403/10 ,  C07D403/12 ,  Y02P20/55

摘要： The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

摘要翻译： 本公开涉及选自式（I）化合物及其药学上可接受的盐的至少一种实体：其中可变基团X，R 1，R 2，R 3 m，n和p如本文所定义。 本公开还涉及制备至少一种这样的实体的方法和用于其制备的中间体，含有至少一种这样的实体的药物组合物，至少一种这样的实体在制备药物中的用途， 并涉及至少一种此类实体在治疗诸如变应性疾病，自身免疫疾病，病毒性疾病和癌症等病症中的用途。

公开(公告)号：EP3450433A1

公开(公告)日：2019-03-06

申请号：EP17789569.5

申请日：2017-04-25

申请人： Sumitomo Dainippon Pharma Co., Ltd.

发明人： TOJO, Shingo ,  ISOBE, Yoshiaki ,  IDEUE, Eiji ,  FUJIWARA, Hiroaki ,  URABE, Daisuke

IPC分类号： C07D473/22 ,  A61K31/52 ,  A61K31/5377 ,  A61P37/06 ,  A61P43/00 ,  C07D487/04 ,  C07D519/00

摘要： The present invention relates to a substituted purine derivative of formula (1) wherein R 1 is alkoxy or the like, R 2 is alkyl or the like, Ring Q 1 is aryl or the like, W 1 is alkylene or the like, Ring Q 2 is aromatic carbocyclyl or the like, n is 1 - 4, R 3 is hydrogen atom or the like, X 1 is single bond or the like, W 2 is alkylene or the like, and R 4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.

公开(公告)号：EP2850067A1

公开(公告)日：2015-03-25

申请号：EP13791057.6

申请日：2013-05-17

申请人： Sumitomo Dainippon Pharma Co., Ltd. ,  Astrazeneca Aktiebolag

发明人： HORI, Seiji ,  HASEGAWA, Futoshi ,  URABE, Daisuke ,  KUREBAYASHI, Hirotaka

IPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61P11/00 ,  A61P31/00 ,  A61P35/00 ,  A61P43/00 ,  C07D239/47 ,  C07D403/10 ,  C07D403/12

CPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  C07D239/47 ,  C07D239/49 ,  C07D403/10 ,  C07D403/12 ,  Y02P20/55

摘要： The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

摘要翻译： 本公开涉及从式（I）的化合物及其药学上可接受的盐中选择的至少一个实体：（I）其中可变基团X，R 1，R 2，R 3 m，n和p如本文所定义。 本公开还涉及用于制备至少一种这样的实体的方法，以及可用于其制备的中间体，含有至少一个这样的实体的药物组合物，至少一种这样的实体在制备药物中的用途， 以及至少一种这样的实体在治疗诸如过敏性疾病，自身免疫性疾病，病毒性疾病和癌症的病症中的用途。